GlobeNewswire Inc | Jan 4, 2021 04:34PM EST

January 04, 2021

Aspira to participate in the 10th Annual LifeSci Advisors Corporate Access Event andBiotech Showcase from January 6 15th, 2021

AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced management will participate in the LifeSci Advisors Corporate Access Event taking place between January 6-8 and 11-14 and the 2021 Biotech Showcase Virtual Event taking place on January 11-15.

Valerie Palmieri, President and Chief Executive Officer, and Robert Beechey, Chief Financial Officer will be available for 1x1 meetings with investors during the LifeSci Advisors Corporate Access Event and will be participating in a panel entitled, Innovations in Cancer Diagnostics. A registration link and details are below.

Management will also be participating in Biotech Showcase 2021, and providing an on-demand company presentation. Biotech Showcase is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.

2021 LifeSci Advisors Corporate Access EventDate: January 6-8 and 11-14, 2021Link to Register: Click Here to Register

2021 LifeSci Advisors Panel Presentation, Innovations in Cancer DiagnosticsDate: January 7, 2021Time: 4:00-5:00pm ESTLink to Register: Click Here to Register

2021 Biotech Showcase (On-Demand Corporate Presentation)Date: January 11-15, 2021Link to Register: https://informaconnect.com/biotech-showcase/

About Aspira Womens Health, Inc.Aspira Womens Health, Inc. (formerly known as Vermillion Inc.,Nasdaq:VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.OVA1plus includes our FDA-cleared products, OVA1and OVERAto detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus.With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVANEXand EndoCheck.Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com